Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Cristina De Ramón, Jose Angel Hernandez-Rivas, MD PhD, Jose Antonio Rodríguez García, Enrique M. Ocio, MDPhD, María Teresa Gómez-Casares, MD PhD, Javier López Jiménez, MD PhD, Carlos Solano, MD PhD, Joaquín Martínez-López, Anna Sureda, Manuel Jurado, MD PhD, Raul Córdoba, MD PhD, Celina Benavente, Pascual Marco, Jose Antonio Pérez-Simón, MD, Jose Maria Moraleda, MD PhD, Angela Figuera, Emilia Pardal, Cristina Pascual Izquierdo, PhD MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142292

Published: 2020

Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140934

Published: 2020

Journal Articles

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Enrique M. Ocio, MDPhD, Yvonne A. Efebera, MD MPH, Roman Hájek, MD PhD, Miquel Granell, MD, Vladimir Maisnar, MD, Jan Straub, MD, Jean-Richard Eveillard, MD, Lionel Karlin, MD, Vincent Ribrag, MD, María-Victoria Mateos, MD PhD, Albert Oriol, Malin Sydvander, MSc, Stefan Norin, MD, Sofia Mannikko, MSc, Luděk Pour, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-135991

Published: 2020

Journal Articles

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Rosalinda Termini, Evangelos Terpos, MDPhD, Albert Pérez, MD, Tomas Jelinek, Nikoletta-Aikaterini Kokkali, Joan Bargay, MD, Fernando Solano Ramos, MD PhD, Sara Rodríguez, PhD, Cristina Pérez Ruiz, Catarina Maia, Antonio Sacco, RN, Marco Chiarini, MSc, Viviana Giustini, MSc, Jill Corre, PharmD, PhD, Francois Vergez, DVM, PhD, Marc S. Raab, MD, Niels Weinhold, PhD, Aitziber Lopez Lopez, Sonia Garate, Diego Alignani, PhD, Sarvide Sarai, Remco Loos, Antoni Garcia-Guiñon, MD, Maialen Sirvent, José Enrique de la Puerta, Rebeca Iglesias, Maria Casanova, MD, Maria Elena Cabezudo, Valentin Cabañas, MD, Enrique M. Ocio, MDPhD, Joaquin Martinez-Lopez, MD, Javier de la Rubia, Artur Paiva, Helena Vitoria, Catarina Geraldes, MD PhD, Roman Hajek, MD, Heinz Ludwig, MD, Hartmut Goldschmidt, MD, Herve Avet-Loiseau, Aldo M. Roccaro, MDPhD, Jesús F. San-Miguel, Bruno Paiva, PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136251

Published: 2020

Journal Articles

Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study

Enrique M. Ocio, MDPhD, Aurore Perrot, Pierre Bories, MD, Jesus F. San-Miguel, MD PhD, Igor W Blau, MD PhD, Lionel Karlin, MD, Joaquin Martinez-Lopez, MD PhD, Wolfram Pönisch, MD, Sara Bringhen, MD, Fabio Ciceri, MD, María-Victoria Mateos, MD PhD, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Thomas Fitzmaurice, PhD, Corina Oprea, MD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136569

Published: 2020

Journal Articles

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Enrique M. Ocio, MDPhD, Sara Bringhen, MD, Stefania Oliva, MD, Paula Rodriguez-Otero, MD PhD, Dheepak Kanagavel, MD PhD, Corina Oprea, MD, Vivian Wei, Severine Doroumian, Joaquin Martinez-Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 3160.

https://doi.org/10.1182/blood.V130.Suppl_1.3160.3160

Published: 2017

Journal Articles

Immune Predictors of Response to Pembrolizumab Monotherapy As Consolidation in Multiple Myeloma Patients: Results of the GEM-Pembresid Clinical Trial

Enrique M. Ocio, MDPhD, Noemi Puig, MD PhD, Luis Corchete, José J Pérez, Julio Dávila, Teresa Paíno, Javier de la Rubia, Albert Oriol, MD, Jesús Martín, Felipe De Arriba, PhD, Joan Bladé, MD PhD, M Jesús Blanchard, Ramón García-Sanz, MD, Bruno Paiva, PhD, Juan-José Lahuerta, Jesus F. San Miguel, MD, Maria-Victoria Mateos, MD

Blood (2017) 130 (Supplement 1): 1874.

https://doi.org/10.1182/blood.V130.Suppl_1.1874.1874

Published: 2017

Journal Articles

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1886.

https://doi.org/10.1182/blood.V130.Suppl_1.1886.1886

Published: 2017

Journal Articles

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Xiaozhong Qian, Meletios A. Dimopoulos, Michael Amatangelo, PhD, Chad Bjorklund, Katja C. Weisel, Enrique M. Ocio, MDPhD, Xin Yu, Teresa Peluso, Lars Sternas, Mohamed Zaki, Philippe Moreau, MDPhD, Anjan Thakurta, PhD

Blood (2017) 130 (Supplement 1): 3109.

https://doi.org/10.1182/blood.V130.Suppl_1.3109.3109

Published: 2017

Journal Articles

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

Enrique M. Ocio, MDPhD, Cristina Motllo, Paula Rodriguez-Otero, MD PhD, Joaquin Martinez-Lopez, MD PhD, Javier de la Rubia, Jesús Martín, Joan Bladé, MD PhD, María-Dolores García-Malo, Luis Palomera, Aránzazu García-Mateo, Felipe De Arriba, PhD, Ramón García-Sanz, MD, Albert Oriol, MD, Juan-José Lahuerta, Jesus F. San Miguel, MD, Maria-Victoria Mateos, MD

Blood (2017) 130 (Supplement 1): 1873.

https://doi.org/10.1182/blood.V130.Suppl_1.1873.1873

Published: 2017

Journal Articles

New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1783.

https://doi.org/10.1182/blood.V130.Suppl_1.1783.1783

Published: 2017

NARROW

Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety

Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study

A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

Immune Predictors of Response to Pembrolizumab Monotherapy As Consolidation in Multiple Myeloma Patients: Results of the GEM-Pembresid Clinical Trial

Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone Vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma

Correlative Analyses of Cereblon ( CRBN ), cMYC , IRF4 , BLIMP1 , and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Safety and Efficacy of Filanesib in Combination with Pomalidomide and Dexamethasone in Refractory MM Patients. Phase Ib/II Pomdefil Clinical Trial Conducted By the Spanish MM Group

New Alternatives for the Evaluation of Minimal Residual Disease (MRD) Detection By Next Generation Sequencing in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only